(Reuters) - Aduro Biotech Inc said its pancreatic cancer drug did not improve overall survival in patients who did not show improvement after at least two prior therapies, in a mid-stage study.
In the study, patients were given either CRS-207 or chemotherapy or a combination of CRS-207 with Aduro’s GVAX Pancreas, the company said on Monday.
Aduro’s shares fell 33 percent to $7.14 in premarket trading.
Reporting by Ankur Banerjee in Bengaluru; Editing by Kirti Pandey
Our Standards: The Thomson Reuters Trust Principles.